Results 31 to 40 of about 575,334 (316)

The epithelial barrier theory proposes a comprehensive explanation for the origins of allergic and other chronic noncommunicable diseases

FEBS Letters, EarlyView.
Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu, Huseyn Babayev, Ismail Ogulur, Sena Ardicli, Yagiz Pat, Duygu Yazici, Bingjie Zhao, Lihong Chang, Xiaoqing Liu, Paolo D'Avino, Manru Li, Ceren Biçer, Fatma Hacer Kurtoğlu Babayev, Raja Dhir, Kari C. Nadeau, Marie‐Charlotte Brüggen, Mubeccel Akdis, Cezmi A. Akdis   +17 more
wiley   +1 more source

The role of culturally appropriate interpersonal communication strategies to reduce hepatitis B and liver cancer disparities

Frontiers in Public Health
IntroductionAsian and Pacific Islander (API), African, and Caribbean immigrant groups in the U.S. are disproportionately impacted by chronic hepatitis B and hepatocellular carcinoma (primary liver cancer).
Beatrice Zovich, Suzanne J. Block, Fiona Borondy-Jenkins, Kate Moraras, Thomas Chen, Rukayat Adedokun, Dung Hua, Chari Cohen   +7 more
doaj   +1 more source

Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells

FEBS Letters, EarlyView.
Imeglimin, at clinically relevant concentrations, inhibits vesicular ATP accumulation and release from hepatic stellate cells, thereby attenuating purinergic signaling and reducing fibrogenic activation. This mechanism reveals a newly identified antifibrotic action of imeglimin beyond glycemic control.
Seiji Nomura, Lixiang Wang, Nao Hasuzawa, Ayako Nagayama, Sawako Moriyama, Kenji Ashida, Yoshinori Moriyama, Masatoshi Nomura, Ken Yamamoto   +8 more
wiley   +1 more source

The burden of chronic hepatitis B virus infection in Australia, 2011

Australian and New Zealand Journal of Public Health, 2013
Objective: The number of Australians living with chronic hepatitis B (CHB) is thought to be increasing, as are adverse outcomes including cirrhosis and liver cancer, however, robust, up‐to‐date estimates of this burden are limited. Contemporary estimates
Jennifer H. MacLachlan, Nicole Allard, Vanessa Towell, Benjamin C. Cowie   +3 more
doaj   +1 more source

Epidemiology of hepatitis B [PDF]

The Pediatric Infectious Disease Journal, 1993
An estimated 200,000 to 300,000 hepatitis B virus infections occur annually in the United States. With acute infection, symptoms develop in fewer than 5% of infants, 5 to 15% of children between the ages of 1 and 5 years and 33 to 50% of older children and adults. However, the risk of chronic infection after acute infection is inversely proportional to
openaire   +3 more sources

Management of acute hepatitis B and reactivation of hepatitis B [PDF]

Liver International, 2013
AbstractThe natural course of hepatitis B virus infection and the resulting hepatic injury is determined by the degree of virus replication and the intensity of host immune response. Upon exposure to hepatitis B virus (HBV), individuals with a vigorous and broad immune response develop acute self‐limited infection, which may result in acute hepatitis ...
Manoj Kumar, Shiv Kumar Sarin, Ankur Jindal   +2 more
openaire   +3 more sources

Reciprocal control of viral infection and phosphoinositide dynamics

FEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source

Survey of lived experiences and challenges in hepatitis B management and treatment

BMC Public Health
Almost 300 million people are living with chronic hepatitis B infection worldwide and most remain undiagnosed and at risk for liver cancer. In 2015 the World Health Organization (WHO) developed guidelines for the prevention, care, and treatment of ...
Catherine Freeland, Charles Adjei, Jack Wallace, Su Wang, Jessica Hicks, Danjuma Adda, Cary James, Chari Cohen   +7 more
doaj   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Prevention Of Hepatitis B

Journal of Education, Health and Sport, 2017
Kowalska Marta Estera, Kalinowski Paweł, Bojakowska Urszula. Prevention of hepatitis B. Journal of Education, Health and Sport. 2017;7(7):315-321. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.831803 http://ojs.ukw.edu.pl/index.php/johs/article/view/4628 The journal has had 7 points in Ministry of Science and Higher ...
Urszula Bojakowska, Paweł Kalinowski, Marta Estera Kowalska   +2 more
openaire   +3 more sources